<DOC>
	<DOC>NCT01368562</DOC>
	<brief_summary>This is an open label compassionate use study of subcutaneously administered MNTX in subjects with advance medical illness and opioid-induced constipation. Eligible subjects were to initially receive a single dose of MNTX delivered SC. Subsequent dosing could have been adjusted upward to achieve a desired clinical response or lowered to alleviate drug related adverse events (AEs).</brief_summary>
	<brief_title>Compassionate Use Study of Methylnaltrexone</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1. Advanced medical illness (i.e. terminal illness, such as incurable cancer or end stage AIDS) with a life expectancy of one to six months 2. On an opioid regimen for the control of pain/discomfort for at least seven days 3. Has opioidinduced constipation 4. On a laxative regimen (e.g. stool softener and SENNA or equivalent) for at least 3 days prior to treatment. 1. Patients with known hypersensitivity to methylnaltrexone, naltrexone or naloxone 2. Patients who are constipated with a disease process suggestive of gastrointestinal obstruction, impaction or diagnosed with a current abdominal pathologic process which may represent a nonopioid cause of bowel dysfunction 3. Patients who are constipated and have active, clinically significant diverticulitis 4. Patients being treated with opioids for diarrhea, dyspnea, cough, pulmonary edema, or congestive heart failure 5. Individuals with a known drug addiction.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>